When combined with a chemotherapy treatment, the drug failed to slow lung cancer progression or significantly impact survival time.
The drug was previously shown promise to do so in a Phase II trial for non-small cell lung cancer, said Sean Bohen, AstraZeneca’s head of medicines development.
This is not the first time selumetinib has disappointed. In July, the drug failed to treat a rare eye cancer. Researchers believe the drug may still play a role in treating one type of thyroid cancer and cancers growing on nerve tissue.
On Friday, New York City-based Bristol-Myers Squibb’s cancer drug Opdivo also failed in a study to treat lung cancer patients.
More articles on the drug market:
Valeant enters licensing agreement with Norgine
Merck’s blockbuster drug Keytruda approved to treat head and neck cancer
AbbVie sues Amgen for patent infringement on Humira: 5 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
